Cargando…
Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705902/ https://www.ncbi.nlm.nih.gov/pubmed/33043992 http://dx.doi.org/10.1111/1759-7714.13690 |
| _version_ | 1783617044421279744 |
|---|---|
| author | Qiu, Hai‐Bo |
| author_facet | Qiu, Hai‐Bo |
| author_sort | Qiu, Hai‐Bo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7705902 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | John Wiley & Sons Australia, Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-77059022020-12-09 Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma Qiu, Hai‐Bo Thorac Cancer Editorials John Wiley & Sons Australia, Ltd 2020-10-12 2020-12 /pmc/articles/PMC7705902/ /pubmed/33043992 http://dx.doi.org/10.1111/1759-7714.13690 Text en © 2020 The Author. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Editorials Qiu, Hai‐Bo Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma |
| title | Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma |
| title_full | Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma |
| title_fullStr | Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma |
| title_full_unstemmed | Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma |
| title_short | Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma |
| title_sort | safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma |
| topic | Editorials |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705902/ https://www.ncbi.nlm.nih.gov/pubmed/33043992 http://dx.doi.org/10.1111/1759-7714.13690 |
| work_keys_str_mv | AT qiuhaibo safetyandefficacyoftislelizumabpluschemotherapyforfirstlinetreatmentofadvancedesophagealsquamouscellcarcinomaandgastricgastroesophagealjunctionadenocarcinoma |